A Phase 3 interventional study of Ranibizumab 0.5mg and Ranibizumab 0.5mg in Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis Pharmaceuticals. Completed at 91 sites in 19 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 11th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2013, is one of 31 in phase 3, and was the 79th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 650 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 5th largest by enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2013, is one of 23 in phase 3, and was the 28th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
This was a 12-month, phase IIIb, randomized, Visual Acuity assessor-masked, multi-center, interventional study assessing the efficacy and safety of the TER vs monthly regimens of 0.5 mg ranibizumab intravitreal (IVT) injections in patients with newly diagnosed nAMD. Patients will be randomized 1:1 into one of two treatment arms, Treat and Extend or monthly regimens.
There will be 3 periods in this study: Screening period (up to 14days), treatment period (11 months), follow-up period (1 month). At randomization visit patients will be randomized into one of the 2 treatment groups Group I ranibizumab 0.5 mg based on monthly treatment or Group II ranibizumab 0.5 mg based on TER (randomization ratio of 1:1) and will receive the first dose of Investigational treatment. Patients in Group I the following visits will perform on monthly intervals. For patients in Group II the investigator will evaluate disease activity (i.e., signs of exudation) based on SD-OCT, and in case of absence of disease activity every next visit will be 2 weeks), with a maximum of a 12-week interval.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
Drug: Ranibizumab 0.5mg
Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
Drug: Ranibizumab 0.5mg
0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
Also known as: Lucentis
0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
Also known as: Lucentis
Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement
Time frame: Baseline to month 12
Number of Visits Scheduled
The number of visits scheduled according to the treat and extend regimen after treatment initiation
Time frame: From Month1 to Month 11
Change in BCVA From Baseline to Month 12
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters
Time frame: Baseline to Month 12
Average BCVA Change From Baseline to Month 12
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12
Time frame: Baseline and every month for 12 months
Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline
Time frame: Baseline and every month for 12 months
Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline
Time frame: Baseline and every month for 12 months
Number of Patients With Best Corrected Visual Acuity (BCVA) Loss <5, <10, and <15 Letters by Visit
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.
Time frame: Baseline and every month for 12 months
Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome
Time frame: Baseline and every month for 12 months
The Mean Number of Treatment Frequency
The number of injections received
Time frame: Month 12
The Average Number of Days Between Injections
The average dosing interval was measured as the average number of days between injections
Time frame: Month 12
Percentage of Participants With Fluid Free Macula Over Time up to Month 12
OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages
Time frame: Month 12
Change in Central Subfield Retinal Thickness (CSFT) Over Time
OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit
Time frame: Month 12
Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at
To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.
Time frame: Month 12
Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)
The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome
Time frame: Baseline, Month 12
| Milestone | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Started | 323 | 327 |
| Safety set | 323 | 326 |
| Completed | 290 | 295 |
| Not completed | 33 | 32 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Protocol deviation | 1 | 2 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Withdrawal by subject | 14 | 17 |
| Withdrew: Adverse event | 9 | 2 |
| Withdrew: Death | 3 | 4 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement
| Letters (EDTRS) | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 | 6.2 ± 0.70 | 8.1 ± 0.70 |
The number of visits scheduled according to the treat and extend regimen after treatment initiation
| Number of visits | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Number of Visits Scheduled | 8.9 ± 2.56 | 11.2 ± 2.37 |
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters
| Letters (EDTRS) | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Change in BCVA From Baseline to Month 12 | 6.4 ± 14.11 | 8.0 ± 11.61 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12
| Letters (EDTRS) | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Average BCVA Change From Baseline to Month 12 | 6.3 ± 10.50 | 7.1 ± 9.41 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline
| Letters (EDTRS) | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Month 1 (n=320, 322) | 4.6 ± 7.56 | 4.2 ± 6.98 |
| Month 2 (n=240, 316) | 5.5 ± 8.64 | 5.8 ± 8.58 |
| Month 3 (n=247, 311) | 6.7 ± 9.09 | 6.7 ± 9.19 |
| Month 4 (n=213, 314) | 7.0 ± 10.90 | 7.3 ± 9.95 |
| Month 5 (n=231, 302) | 6.0 ± 11.34 | 7.7 ± 10.61 |
| month 6 (n=205, 302) | 6.9 ± 13.34 | 7.9 ± 10.83 |
| Month 7 (n=230, 298) | 5.9 ± 14.25 | 7.9 ± 11.36 |
| Month 8 (n=210, 295) | 7.5 ± 12.87 | 7.9 ± 11.34 |
| Month 9 (n=179, 295) | 6.6 ± 13.63 | 7.6 ± 12.56 |
| Month 10 (n=202, 296) | 6.3 ± 13.44 | 7.6 ± 12.06 |
| Month 11 (n=180, 290) | 5.9 ± 14.12 | 7.5 ± 12.48 |
| Month 12 (n=294, 295) | 6.6 ± 13.41 | 7.9 ± 11.96 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline
| Number of participants | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Month 1,Gain of ≥ 1 letter (n=320,322) | 235 | 233 |
| Month 1, Gain of ≥ 5 letters | 145 | 145 |
| Month 1, Gain of ≥ 10 letters | 65 | 58 |
| Month 1, Gain of ≥ 15 letters | 24 | 23 |
| Month 1, Gain of ≥ 30 letters | 4 | 2 |
| Month 2, Gain of >= 1 letter (n=226, 316) | 168 | 244 |
| Month 2, Gain of >= 5 letters | 123 | 184 |
| Month 2, Gain of >= 10 letters | 60 | 88 |
| Month 2, Gain of >= 15 letters | 30 | 39 |
| Month 2, Gain of >= 30 letters | 4 | 3 |
| Month 3, Gain of >= 1 letter (n=161,311) | 120 | 244 |
| Month 3, Gain of >= 5 letters | 98 | 187 |
| Month 3, Gain of >= 10 letters | 57 | 110 |
| Month 3, Gain of >= 15 letters | 28 | 46 |
| Month 3, Gain of >= 30 letters | 2 | 3 |
| Month 4, Gain of >= 1 letter (n=128, 314) | 96 | 249 |
| Month 4, Gain of >= 5 letters | 67 | 198 |
| Month 4, Gain of >=10 letters | 48 | 118 |
| Month 4, Gain of >= 15 letters | 25 | 60 |
| Month 4, Gain of >= 30 letters | 4 | 8 |
| Month 5, Gain of >= 1 letter (n=114, 302) | 84 | 243 |
| Month 5, Gain of >= 5 letters | 64 | 197 |
| Month 5, Gain of >= 10 letters | 42 | 116 |
| Month 5, Gain of >= 15 letters | 19 | 59 |
| Month 5, Gain of >= 30 letters | 3 | 10 |
| Month 6, Gain of >= 1 letter (n=117, 302) | 85 | 238 |
| Month 6, Gain of >= 5 letters | 68 | 197 |
| Month 6, Gain of >= 10 letters | 42 | 125 |
| Month 6, Gain of >= 15 letters | 19 | 61 |
| Month 6, Gain of >= 30 letters | 2 | 11 |
| Month 7, Gain of >= 1 letter (n=176, 298) | 126 | 235 |
| Month 7, Gain of >= 5 letters | 94 | 196 |
| Month 7, Gain of >= 10 letters | 57 | 123 |
| Month 7, Gain of >= 15 letters | 33 | 69 |
| Month 7, Gain of >= 30 letters | 7 | 9 |
| Month 8, Gain of >= 1 letter (n=163, 295) | 124 | 228 |
| Month 8, Gain of >= 5 letters | 108 | 198 |
| Month 8, Gain of >= 10 letters | 69 | 130 |
| Month 8, Gain of >= 15 letters | 40 | 72 |
| Month 8, Gain of >= 30 letters | 4 | 9 |
| Month 9, Gain of >= 1 letter (n=129, 295) | 93 | 229 |
| Month 9, Gain of >= 5 letters | 78 | 186 |
| Month 9, Gain of >= 10 letters | 52 | 128 |
| Month 9, Gain of >= 15 letters | 28 | 70 |
| Month 9, Gain of >= 30 letters | 5 | 8 |
| Month 10, Gain of >= 1 letter (n=159, 296) | 113 | 230 |
| Month 10, Gain of >= 5 letters | 98 | 190 |
| Month 10, Gain of >= 10 letters | 60 | 126 |
| Month 10, Gain of >= 15 letters | 32 | 74 |
| Month 10, Gain of >= 30 letters | 4 | 10 |
| Month 11, Gain of >= 1 letter (131, 290) | 94 | 222 |
| Month 11, Gain of >= 5 letters | 79 | 187 |
| Month 11, Gain of >= 10 letters | 51 | 130 |
| Month 11, Gain of >= 15 letters | 32 | 74 |
| Month 11, Gain of >= 30 letters | 5 | 9 |
| Month 12, Gain of >= 1 letter (n=291, 295) | 217 | 226 |
| Month 12, Gain of >= 5 letters | 178 | 199 |
| Month 12, Gain of >= 10 letters | 123 | 135 |
| Month 12, Gain of >= 15 letters | 75 | 77 |
| Month 12, Gain of >= 30 letters | 12 | 8 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.
| Number of participants | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Month 1, Loss of < 5 letters (n=320, 322) | 296 | 295 |
| Month 1, Loss of < 10 letters | 313 | 314 |
| Month 1, Loss of < 15 letters | 319 | 320 |
| Month 2, Loss of < 5 letters (n=226, 316) | 205 | 288 |
| Month 2, Loss of < 10 letters | 220 | 306 |
| Month 2, Loss of < 15 letters | 223 | 309 |
| Month 3, Loss of < 5 letters (n=161, 311) | 146 | 289 |
| Month 3, Loss of < 10 letters | 158 | 299 |
| Month 3, Loss of < 15 letters | 160 | 304 |
| Month 4, Loss of < 5 letters (n=128, 314) | 114 | 286 |
| Month 4, Loss of < 10 letters | 128 | 301 |
| Month 4, Loss of < 15 letters | 124 | 307 |
| Month 5, Loss of < 5 letters (n=114, 302) | 97 | 276 |
| Month 5, Loss of < 10 letters | 105 | 287 |
| Month 5, Loss of < 15 letters | 108 | 295 |
| Month 6, Loss of < 5 letters (n=117, 302) | 104 | 271 |
| Month 6, Loss of < 10 letters | 110 | 286 |
| Month 6, Loss of < 15 letters | 111 | 298 |
| Month 7, Loss of < 5 letters (n=176, 298) | 148 | 268 |
| Month 7, Loss of < 10 letters | 162 | 279 |
| Month 7, Loss of < 15 letters | 166 | 289 |
| Month 8, Loss of < 5 letters (n=163, 295) | 145 | 262 |
| Month 8, Loss of < 10 letters | 155 | 276 |
| Month 8, Loss of < 15 letters | 155 | 286 |
| Month 9, Loss of < 5 letters (n=129, 295) | 110 | 258 |
| Month 9, Loss of < 10 letters | 120 | 270 |
| Month 9, Loss of < 15 letters | 122 | 281 |
| Month 10, Loss of < 5 letters(n=159, 296) | 133 | 253 |
| Month 10, Loss of < 10 letters | 147 | 276 |
| Month 10, Loss of < 15 letters | 150 | 285 |
| Month 11, Loss of < 5 letters (n=131, 290) | 105 | 251 |
| Month 11, Loss of < 10 letters | 118 | 263 |
| Month 11, Loss of < 15 letters | 121 | 275 |
| Month 12, Loss of < 5 letters (291, 295) | 247 | 256 |
| Month 12, Loss of < 10 letters | 267 | 272 |
| Month 12, Loss of < 15 letters | 273 | 284 |
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome
| Number of participants | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Month 1 (n=320, 322) | 106 | 106 |
| Month 2 (n=226, 316) | 74 | 136 |
| Month 3 (n=161, 311) | 67 | 148 |
| Month 4 (n=128, 314) | 60 | 147 |
| Month 5 (n=114, 302) | 51 | 156 |
| Month 6 (n=117, 302) | 58 | 155 |
| Month 7 (n=176, 298) | 78 | 150 |
| Month 8 (n=163, 295) | 84 | 155 |
| Month 9 (n=129, 295) | 68 | 156 |
| Month 10 (n=159, 296) | 74 | 149 |
| Month 11 (n=131, 290 | 63 | 143 |
| Month 12 (n=291, 295) | 131 | 149 |
The number of injections received
| Number of injections | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| The Mean Number of Treatment Frequency | 8.7 ± 2.68 | 11.0 ± 2.50 |
The average dosing interval was measured as the average number of days between injections
| days | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| The Average Number of Days Between Injections | 40.3 ± 11.28 | 29.4 ± 3.27 |
OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages
| Percentage of participants | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Absent | 60.5 | 60.7 |
| Definite | 39.5 | 39 |
| Can't grade | 0.0 | 0.3 |
OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit
| microns | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Month 1 (n=311, 316) | -137.6 ± 132.33 | -126.8 ± 119.47 |
| Month 2 (n=220, 311) | -151.6 ± 151.15 | -149.2 ± 137.60 |
| Month 3 (n=157, 304) | -149.8 ± 167.26 | -151.8 ± 149.51 |
| Month 4 (n=125, 307) | -141.8 ± 183.71 | -161.3 ± 149.36 |
| Month 5 (n=110, 295) | -138.6 ± 160.04 | -160.9 ± 148.23 |
| Month 6 (n=113, 298) | -140.1 ± 156.25 | -163.4 ± 157.18 |
| Month 7 (n=173, 296) | -146.6 ± 160.72 | -166.9 ± 161.49 |
| Month 8 (n=159, 290) | -153.4 ± 151.93 | -170.4 ± 156.68 |
| Month 9 (n=126, 286) | -150.2 ± 153.82 | -169.3 ± 156.50 |
| Month 10 (n=156, 291) | -154.6 ± 162.77 | -170.9 ± 153.90 |
| Month 11 (n=127, 285) | -133.1 ± 170.47 | -174.8 ± 163.16 |
| Month 12 (n=289, 287) | -172.1 ± 162.81 | -173.3 ± 154.13 |
To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.
| Percentage of participants | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Yes | 18.7 | 17.1 |
| No | 74.1 | 76.9 |
| Can't grade | 0.0 | 2.4 |
| Not applicable | 7.2 | 3.5 |
The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome
| Score on a scale | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) | 2.3 ± 13.93 | 4 ± 13.72 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group I Ranibizumab 0.5 mg TER | — | 39/323 (12.1%) | 164/323 (50.8%) |
| Group II Ranibizumab 0.5 mg Monthly | — | 42/326 (12.9%) | 166/326 (50.9%) |
| Event | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| PneumoniaInfections and infestations | 4/323 | 2/326 |
| Transient ischaemic attackNervous system disorders | 3/323 | 1/326 |
| Myocardial infarctionCardiac disorders | 2/323 | 0/326 |
| VertigoEar and labyrinth disorders | 2/323 | 0/326 |
| BronchitisInfections and infestations | 2/323 | 0/326 |
| Femur fractureInjury, poisoning and procedural complications | 2/323 | 0/326 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/323 | 1/326 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/323 | 1/326 |
| HypotensionVascular disorders | 2/323 | 0/326 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/323 | 2/326 |
| Event | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly |
|---|---|---|
| Intraocular pressure increased (Study eye)Investigations | 27/323 | 28/326 |
| NasopharyngitisInfections and infestations | 18/323 | 26/326 |
| HypertensionVascular disorders | 23/323 | 13/326 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 14/323 | 19/326 |
| Neovascular age-related macular degeneration (Fellow eye)Eye disorders | 8/323 | 16/326 |
| Visual acuity reduced (Study eye)Eye disorders | 15/323 | 12/326 |
| BronchitisInfections and infestations | 6/323 | 12/326 |
| InfluenzaInfections and infestations | 9/323 | 12/326 |
| Eye pain (Study eye)Eye disorders | 10/323 | 5/326 |
| Conjunctivitis (Study eye)Infections and infestations | 10/323 | 6/326 |
| Age, Continuous(Years) | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly | Total |
|---|---|---|---|
| Mean | 75.3 ± 8.61 | 75.2 ± 8.13 | 75.2 ± 8.37 |
| Sex: Female, Male(Participants) | Group I Ranibizumab 0.5 mg TER | Group II Ranibizumab 0.5 mg Monthly | Total |
|---|---|---|---|
| Female | 179 | 181 | 360 |
| Male | 144 | 146 | 290 |
Ran from Dec 2013 to primary completion in Nov 2015, 23 months.
Results were first posted in Dec 2016, 1 year after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 23 months is close to that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab